课题基金 / 基金详情

Vision-QOL-CAT: A Functional Health CAT for those with Visual Disorders

Vision-QOL-CAT: A Functional Health CAT for those with Visual Disorders
Vision-QOL-CAT:针对视觉障碍患者的功能健康 CAT
批准号:
8057033
负责人:
JOHN E WARE
金额:
$9.86万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-02-01 至 2012-12-31

项目摘要

项目成果

JOHN E WARE的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):随着人口老龄化,视力丧失是一个日益严重的公共卫生问题,影响了300多万美国人。眼病对健康相关生活质量(HRQOL)的影响和新疗法的益处尚未得到很好的理解,也未与其他医疗条件进行比较。虽然有测量视觉障碍影响的自我评估工具(如VF-14、ADVS、NEI-VFQ),但在广泛的功能健康水平和综合领域中更有效地测量视觉障碍影响的工具的开发还没有跟上通用HRQOL工具取得的进展。我们建议使用项目反应理论(IRT)和计算机化自适应测试(CAT)技术,在其他条件的研究中得到证实,建立一个更有效的患者报告结果(PRO)仪器(VISION-QOL-CAT)来测量成人视觉障碍的影响。CATs为每个领域的每个人量身定制问题,从而在不增加应答者负担的情况下提高了测量的精度和范围。我们第一阶段的目标是:(1)构建和管理(N=300)新的视觉特异性HRQOL题库,以测量视觉障碍的影响,并对其有用性进行初步的心理测量和临床评估;(2)开发全面的(视觉专用和通用的)、灵活的VISION-QOL-CAT原型解决方案;(3)在视力诊所设置中,将原型工具与现有的“遗留”全长静态问卷进行比较,进行先导测试(N=100)。我们将与马萨诸塞大学纪念眼科中心合作,对不同视力丧失严重程度的成年患者进行实地调查,包括“湿”型和“干”型与年龄相关的黄斑变性。第一阶段的产品将是一个全面的原型VISION-QOL- CAT,具有可行性、可接受性和经验性能方面的初步证据,并与静态通用和视觉专用HRQOL工具进行比较。在第二阶段,该系统将被扩展(内容)和改进(管理效率、可靠范围、心理测量和效用指数评分选项、患者和提供者报告、用户友好文档),并在不同平台(例如iPod/iPhone/iPad、基于互联网的、PC、电话IVR)上进一步进行定性和定量评估(心理测量、临床反应),并在普通人群和眼病患者中进行规范。通过降低数据收集成本,减轻反应负担,消除“天花板”和“地板”效应,提高个体评分的准确性,可以监测和管理临床研究中观察到的HRQOL结果,以改善对成人视力障碍的护理。
英文摘要
DESCRIPTION (provided by applicant): With the aging of the population, vision loss is a growing public health problem affecting more than 3 million Americans. The impact of eye disease on health-related quality of life (HRQOL) and the benefits of new treatments are not well understood and have not been compared with those for other medical conditions. Although self-assessment tools for measuring the impact of visual disorders (e.g., VF-14, ADVS, NEI-VFQ) are available, the development of instruments that are more efficient in measuring the impact of visual disorders over a wide range of functional health levels and comprehensive domains has not kept pace with advancements achieved for generic HRQOL tools. We propose to use Item Response Theory (IRT) and Computerized Adaptive Testing (CAT) techniques, proven in studies of other conditions, to build a more efficient Patient-Reported Outcomes (PRO) instrument (VISION-QOL-CAT) to measure the impact of adult visual disorders. CATs tailor questions administered to each individual for each domain, thereby increasing precision and range of measurement without increasing respondent burden. Our Phase I aims are to: (1) construct and administer (N=300) new vision-specific HRQOL item banks to measure the impact of visual disorders and perform preliminary psychometric and clinical evaluations of their usefulness; (2) develop a comprehensive (vision-specific and generic HRQOL) and flexible VISION-QOL-CAT prototype solution; and (3) pilot test (N=100) the prototype tool in comparison with existing "legacy" full-length static questionnaires in a vision clinic setting. We will partner with the UMass Memorial Eye Center in fielding surveys of adult patients differing in severity of vision loss, including both "wet" and "dry" types of age- related macular degeneration. The product of Phase I will be a prototype comprehensive VISION-QOL- CAT with preliminary evidence regarding feasibility, acceptability, and empirical performance in comparison with static generic and vision-specific HRQOL tools. In Phase II, the system will be expanded (content) and improved (administration efficiency, reliable range, psychometric and utility index scoring options, patient and provider reports, user-friendly documentation) and further evaluated in both qualitative and quantitative terms (psychometrics, clinical responsiveness) across different platforms (e.g., iPod/iPhone/iPad, Internet-based, PC, telephone IVR), and normed in general populations and among those with eye disease. By lowering data collection costs, reducing response burden, eliminating "ceiling" and "floor" effects and increasing the precision of individual scores, the HRQOL outcomes observed in clinical research may be monitored and managed to improve care for adults with visual disorders. PUBLIC HEALTH RELEVANCE: The VISION-QOL-CAT is a new tool for assessing the impact of visual disorders on quality of life (QOL). The prototype study will provide preliminary evidence regarding feasibility and acceptability of the new tool in a clinical setting. The tool's performance will be compared to other patient-reported QOL tools for measuring generic and vision-specific health outcomes. More practical and useful tools will make it possible to consider functional health and well-being in making treatment decisions and in enabling patients to play a more active role in managing their eye disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Measuring Multimorbidity with Individualized Disease-specific QOL Impact Scales
Development of a Functional Health CAT for Managing Obesity
  • 批准号:
    7272258
  • 项目类别:
  • 资助金额:
    $12.52万
  • 财政年份:
    2007
  • 负责人:
    JOHN E WARE
  • 依托单位:
Functional Health CAT in Chronic Kidney Disease
  • 批准号:
    7053957
  • 项目类别:
  • 资助金额:
    $68.6万
  • 财政年份:
    2006
  • 负责人:
    JOHN E WARE
  • 依托单位:
Functional Health CAT in Chronic Kidney Disease
  • 批准号:
    7227816
  • 项目类别:
  • 资助金额:
    $74.91万
  • 财政年份:
    2006
  • 负责人:
    JOHN E WARE
  • 依托单位:
海外基金